Want to see CH:GALD full AI Analyst Report?
GALD Stock Chart & Stats
CHF156.85
-CHF8.02(-7.15%)
At close: 4:00 PM EST
CHF156.85
-CHF8.02(-7.15%)
Day’s Range― - ―
52-Week RangeCHF122.70 - CHF188.25
Previous CloseN/A
Volume230.69K
Average Volume (3M)337.59K
Market Cap
CHF40.51B
Enterprise ValueCHF52.72B
Total Cash (Recent Filing)CHF780.00M
Total Debt (Recent Filing)CHF2.75B
Price to Earnings (P/E)79.4
Beta0.80
Next Earnings
Jul 23, 2026EPS Estimate
1.43Next Dividend Ex-DateN/A
Dividend Yield0.2%
Share Statistics
EPS (TTM)2.69
Shares Outstanding237,897,630
10 Day Avg. Volume210,266
30 Day Avg. Volume337,589
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.94
Price to Sales (P/S)9.24
P/FCF Ratio46.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF194.00Price Target Upside23.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)4.63
Revenue Forecast (FY)CHF6.32B
Bulls Say, Bears Say
Bulls Say
Profitability Recovery & High Gross MarginsSustained gross margins near 67–70% and a multi-year swing to profitability indicate durable structural improvement in product mix and cost structure. High margins suggest pricing power in medical aesthetics and consumer brands, supporting long-term cash generation and reinvestment capacity.
Strong 2025 Cash GenerationRobust 2025 FCF strengthens financial resilience by funding debt reduction, dividends, R&D and potential bolt-on acquisitions. High FCF conversion (≈87% of net income) signals improving cash quality and sustainable internal funding, enhancing long-term capital allocation flexibility.
Material Leverage ReductionA sharp drop in leverage and a large equity build materially reduce balance-sheet risk and interest burden, improving strategic optionality. Lower leverage supports investment in growth initiatives and makes the company less sensitive to macro shocks over the medium term.
Bears Say
Revenue Dip In 2025Revenue decline amid rising profitability suggests earnings gains were driven by margin expansion or one-off factors rather than top-line momentum. Persistent revenue weakness would limit sustainable growth, constrain pricing leverage over time and raise reliance on cost cuts for profit growth.
Historic Cash-flow VolatilityPrior years of negative or low cash flow indicate operational and cycle volatility; a single-year FCF rebound may not signal lasting stability. If cash generation reverts, it could impede debt reduction, R&D spending and dividend consistency, raising execution risk over the medium term.
Absolute Debt Remains SizableA large nominal debt stock increases exposure to refinancing and interest-rate risks even with improved ratios. Maintaining financial flexibility requires sustained cash conversion; sizable debt could constrain M&A, capex or payouts if revenue or cash generation weakens.
Galderma Group AG News
GALD FAQ
What was Galderma Group AG’s price range in the past 12 months?
Galderma Group AG lowest stock price was CHF122.70 and its highest was CHF188.25 in the past 12 months.
What is Galderma Group AG’s market cap?
Galderma Group AG’s market cap is CHF40.51B.
When is Galderma Group AG’s upcoming earnings report date?
Galderma Group AG’s upcoming earnings report date is Jul 23, 2026 which is in 3 days.
How were Galderma Group AG’s earnings last quarter?
Galderma Group AG released its earnings results on Mar 05, 2026. The company reported CHF1.64 earnings per share for the quarter, beating the consensus estimate of CHF1.273 by CHF0.367.
Is Galderma Group AG overvalued?
According to Wall Street analysts Galderma Group AG’s price is currently Undervalued.
Does Galderma Group AG pay dividends?
Galderma Group AG pays a Notavailable dividend of CHF0.35 which represents an annual dividend yield of 0.2%. See more information on Galderma Group AG dividends here
What is Galderma Group AG’s EPS estimate?
Galderma Group AG’s EPS estimate is 1.43.
How many shares outstanding does Galderma Group AG have?
Galderma Group AG has 237,897,630 shares outstanding.
What happened to Galderma Group AG’s price movement after its last earnings report?
Galderma Group AG reported an EPS of CHF1.64 in its last earnings report, beating expectations of CHF1.273. Following the earnings report the stock price went up 6.975%.
Which hedge fund is a major shareholder of Galderma Group AG?
Currently, no hedge funds are holding shares in CH:GALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
GALD Stock 12 Month Forecast
Average Price Target
CHF194.00
▲(23.69% Upside)